xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

228

KUANetal.

TABLE XXIII.A.5 Evidence surrounding role of chemoradiation therapy in adult rhabdomyosarcoma.

Clinical endpoints 1. LRC 2. Distant control

Study

Year LOE Study design Study groups

Conclusions

Hahnet al. 1239

1. Improved LRC with IMRT 2. No difference in DC

2022 4

Retrospective case series

Pre-IMRT( n = 17) versus IMRT ( n = 8) in head and neck RMS CRT( n = 25), usually concurrent, vincristine-based in PM-RMS CRT( n = 17), Surgery, chemo, and RT ( n = 7),Other

Barthere

2020 4

Retrospective case series

Response

CR: 56%; progressive disease: 20%; unknown/LTF: 4%

et al. 1249

Dinget al. 1240

Worse overall survival for RMS compared to other sarcomas 20.6% vs. 66.9% ( p = 0.001)

1. LRFS 2. DMFS 3. OS

2019 4

Retrospective case series

treatment ( n = 3). Vincristine-based, 56.7% Sinonasal RMS

Stepan et al. 1241

2017 4

Retrospective database study (NCDB)

CRT( n = 90, 49.5%), surgery, chemo, and RT( n = 47, 25.8%), chemo only ( n = 31, 17%), other ( n = 14, 7.7%) in sinonasal

OS

1. 5-year OS 28.4%; survival varied by RMS subtype and age of patient 2. Variable treatment according to clinical factors (e.g., metastases, intracranial involvement).

RMS. Chemo regiment not specified.

Outcome

1. Alive NED: 18, AWD: 7, Dead NED: 1, DWD: 26 2. Multimodality therapies involving chemotherapy regimens should be considered in sinonasal tract alveolar RMS due to a high likelihood of local and distant metastases

Thompson et al. 1250

2017 4

Retrospective case series

CRT( n = 38), chemo only ( n = 7), RTonly ( n = 4), unknown ( n = 3). Some received surgical resection as part of treatment ( n = 16) in Sinonasal tract alveolar RMS Chemonot specified. ( n = 48; chemo: 75%, surgery: 68.8%). Chemo given as adjuvant, neoadjuvant, or both in sinonasal soft tissue sarcoma (48% RMS) chemotherapy ( n = 4) in sinonasal RMS. One received partial resection prior to chemo. Chemo included IVAd with/without etoposide, ifosfamide, cisplatin In entire group First line

Szablewski et al. 1242

2014 4

Retrospective case series

OS

1. Worse survival with RMS compared to other sarcomas 2. Differences in response noted according to surgical resection

1. CR 2. Mortality

1. PR: 75% and CR: 25% 2. Death: 75% during study follow-up

Wagemans et al. 1251

2010 4

Retrospective case series

(Continues)